Efficacy and Safety of Afatinib vs Erlotinib and Gefitinib in EGFR+ NSCLC

(3:7)

How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC

(17:27)

Afatinib vs gemcitabine/cisplatin for advanced NSCLCin Chinese patients - Video Abstract ID 160358

(6:27)

LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC

(2:14)

[lung] Afatinib vs cisplatin chemo for EGFR+ lung cancer: survival data from LUX-Lung trials

(8:3)

GioTag: real world data on first-line afatinib followed by osimertinb

(2:34)

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC

(6:28)

Afatinib vs erlotinib in Chinese patients with advanced SCCof the lung- Video Abstract ID 161506

(6:52)

Afatinib treatment in squamous cell lung cancer – Video abstract [ID 104177]

(4:24)

Second-line afatinib significantly improves PFS in metastatic head and neck cancer

(4:52)

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated adenocarcinoma of the lung

(1:31)

Side Effect Management With Afatinib

(3:8)

LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line

(1:21)

Afatinib Therapy for Uncommon EGFR Alterations in NSCLC

(3:47)

Dr. Bunn Discusses Afatinib in Lung Cancer

(1:25)

Afatinib Plus Cetuximab in Resistant Non-Small Cell Lung Cancer

(8:38)

Dr. Scagliotti on Treating EGFR-Mutated Tumors with Afatinib

(1:16)

Velcheti Gilotrif/ Afatinib in Squamous NSCLC

(4:9)

Afatinib in Chinese NSCLC patients – Video abstract ID 136579

(3:16)

Phase 3 LUX-H\u0026N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma

(3:32)